Gold prices steady ahead of Fed decision; weekly weakness noted
On Monday, Brookline Capital Markets reaffirmed its positive stance on Moderna (NASDAQ:MRNA) shares, maintaining a Buy rating and a price target of $212 - representing significant upside potential from the current price of $27.57, which sits near its 52-week low. According to InvestingPro analysis, Moderna appears undervalued based on its Fair Value metrics. The endorsement follows a series of international regulatory approvals for Moderna’s RESVIA (mRNA-1345), an mRNA vaccine designed to prevent respiratory syncytial virus (RSV). The vaccine received its latest approval in Australia, adding to the momentum built by prior authorizations in the United Kingdom (TADAWUL:4280) last month, Canada in November 2024, and the European Commission in August 2024, which extended mRNA-1345’s reach to all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. Despite recent revenue challenges, with a 52.75% decline in the last twelve months, Moderna maintains a strong financial position with a healthy current ratio of 3.67.
Brookline’s analyst Leah Rush Cann highlighted the vaccine’s competitive edge for the upcoming Fall RSV season, citing its safety profile, the absence of Guillain-Barre syndrome signals, and the convenience of prefilled syringes. The publication of phase III data in the journal Nature in April further supports the vaccine’s potential market competitiveness.
Moderna’s mRNA-1345 is currently available for older adults and is expected to receive authorization for use in adults aged 18-60 in 2025. Brookline Capital Markets forecasts sales of mRNA-1345 to reach $79.6 million in 2025, with the potential to grow to an estimated $3.2 billion in global sales by 2030. These projections underscore the firm’s confidence in the vaccine’s market performance and Moderna’s growth prospects. For deeper insights into Moderna’s financial health and growth potential, access the comprehensive Pro Research Report available exclusively on InvestingPro, along with 10+ additional ProTips and advanced metrics.
In other recent news, Moderna has received approval from the Australian Therapeutic Goods Administration for its mRNA-based RSV vaccine, mRESVIA®, aimed at preventing respiratory diseases in adults aged 60 and over. This is the first mRNA vaccine authorized in Australia for a condition other than COVID-19. Meanwhile, Bernstein SocGen Group has revised Moderna’s stock price target to $39, citing policy uncertainties and a constrained profit and loss statement, while maintaining a Market Perform rating. The firm anticipates Moderna’s revenue to grow from $1.7 billion in 2025 to $9.1 billion by 2034, despite challenges in the COVID and RSV markets.
Additionally, a shakeup at the FDA has seen the departure of Dr. Peter Marks, a key figure in vaccine regulation, which may introduce uncertainty for vaccine developers like Moderna. Furthermore, the U.S. government’s decision to cut funding for Gavi, the Vaccine Alliance, could impact the future demand for vaccines from companies such as Moderna, Novavax (NASDAQ:NVAX), and Pfizer (NYSE:PFE). This reduction in funding is part of a broader decrease in foreign aid, which may affect vaccine availability in developing countries. These developments reflect ongoing challenges and changes in the regulatory and financial landscape affecting Moderna and similar companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.